Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions (EBS) has issued an announcement.
Emergent BioSolutions Inc. secured key contract modifications with U.S. health authorities, bolstering its role in national preparedness. The company will supply additional ACAM2000® smallpox vaccines to the U.S. Strategic National Stockpile under a $99.9 million agreement, and it has also received a $30 million extension to provide more doses of its anthrax vaccine, CYFENDUS™. The news reinforces Emergent’s commitment to support public health through its partnership with the government.
For detailed information about EBS stock, go to TipRanks’ Stock Analysis page.